CRDF
Cardiff Oncology, Inc. NASDAQ Listed Jul 27, 2004$1.30
Mkt Cap $86.9M
52w Low $1.18
3.7% of range
52w High $4.45
50d MA $1.63
200d MA $2.02
P/E (TTM)
—
EV/EBITDA
—
P/B
1.9x
Debt/Equity
0.0x
ROE
-101.0%
P/FCF
-2.3x
RSI (14)
41.50
ATR (14)
$0.15
Beta
1.42
50d MA
$1.63
200d MA
$2.02
Avg Volume
1.5M
Cardiff Oncology, Inc., a clinical-stage oncology company, develops medicine treatment for cancer patients in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor for anti-cancer therapeutics; CY140, an inhibitor of PLK1, PLK2, and PLK3 that is in phase 1/2 studies in solid tumors and leukemias; metastatic colorectal cancer that is in clinical trials; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab. The company's TROV-053 is also in Phase II clinical trial in combination with Zytiga for metastatic castration-resistant prostate cancer. The company primarily serves pharmaceutical manufacturers. The company was formerly known as Trovagene, Inc. and changed its name to Cardiff Oncology, Inc. in May 2012. Cardiff Oncology, Inc. was incorporated in 1999 and is headquartered in San Diego, California.
11055 Flintkote Avenue · San Diego, CA 92121 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 24, 2026 | AMC | -0.18 | -0.11 | +38.9% | 1.70 | +3.5% | +12.4% | +2.6% | -1.0% | +0.0% | -2.6% | — |
| Nov 6, 2025 | AMC | -0.20 | -0.17 | +15.0% | 2.25 | -2.7% | -2.7% | +1.8% | +2.7% | -2.2% | -4.0% | — |
| Jul 29, 2025 | AMC | -0.19 | -0.21 | -10.5% | 3.31 | -18.7% | -24.8% | -4.8% | +11.4% | -4.9% | +2.4% | — |
| May 8, 2025 | AMC | -0.19 | -0.20 | -5.3% | 2.63 | +1.1% | +1.1% | +3.4% | -1.1% | -1.8% | +3.0% | — |
| Feb 27, 2025 | AMC | -0.26 | -0.21 | +19.2% | 4.06 | -0.7% | +4.4% | -9.9% | -2.1% | +14.2% | -9.1% | — |
| Nov 7, 2024 | AMC | -0.27 | -0.25 | +7.4% | 4.09 | +1.0% | -24.7% | +12.3% | -9.2% | -5.4% | -4.4% | — |
| Aug 8, 2024 | AMC | -0.25 | -0.26 | -4.0% | 2.13 | +1.4% | +11.7% | -5.0% | -0.4% | -3.1% | +9.6% | — |
| May 2, 2024 | AMC | -0.25 | -0.22 | +12.0% | 4.48 | -11.2% | -21.4% | -1.7% | -4.3% | -3.3% | +5.6% | — |
| Feb 29, 2024 | AMC | -0.26 | -0.21 | +19.2% | 1.77 | +13.0% | +64.4% | +19.9% | +4.6% | +6.6% | -9.8% | — |
| Nov 2, 2023 | AMC | -0.29 | -0.22 | +24.1% | 1.14 | +5.3% | -2.6% | -2.7% | +0.9% | +0.0% | -10.0% | — |
| Aug 9, 2023 | AMC | -0.27 | -0.25 | +7.4% | 1.91 | +9.9% | +8.4% | -4.3% | +1.0% | +0.0% | -5.5% | — |
| May 4, 2023 | AMC | -0.23 | -0.25 | -8.7% | 1.95 | +2.1% | -3.6% | -4.3% | -1.7% | -3.4% | -1.2% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Jun 3 | Craig Hallum | Downgrade | Buy → Hold | $2 | $1.51 | $1.50 | -0.7% | -7.3% | +10.7% | -3.2% | +0.0% | +2.0% |
| Jun 1 | TD Cowen | Downgrade | Buy → Hold | — | $1.90 | $1.78 | -6.3% | -22.1% | +2.0% | -7.3% | +10.7% | -3.2% |
| Jun 1 | H.C. Wainwright | Downgrade | Buy → Neutral | — | $1.90 | $1.78 | -6.3% | -22.1% | +2.0% | -7.3% | +10.7% | -3.2% |
| Feb 25 | Piper Sandler | Maintains | Overweight → Overweight | — | $1.70 | $1.76 | +3.5% | +12.4% | +2.6% | -1.0% | +0.0% | -2.6% |
| Jan 28 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.00 | $2.03 | +1.5% | -19.0% | +0.0% | +8.0% | -2.3% | -1.8% |
| Aug 6 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.57 | $2.50 | -2.7% | -5.1% | -1.2% | -0.8% | -2.5% | +4.3% |
| May 9 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.63 | $2.66 | +1.1% | +1.1% | +3.4% | -1.1% | -1.8% | +3.0% |
| Feb 28 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $4.06 | $4.03 | -0.7% | +4.4% | -9.9% | -2.1% | +14.2% | -9.1% |
| Dec 13 | Piper Sandler | Maintains | Overweight → Overweight | — | $3.27 | $3.60 | +10.1% | +19.9% | +2.8% | +32.8% | -16.1% | +0.0% |
| Nov 8 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $4.09 | $4.13 | +1.0% | -24.7% | +12.3% | -9.2% | -5.4% | -4.4% |
| May 6 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.52 | $3.55 | +0.9% | -1.7% | -4.3% | -3.3% | +5.6% | +0.3% |
| Mar 6 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.65 | $3.85 | +5.5% | +6.6% | -9.8% | +17.9% | -2.4% | +10.9% |
| Mar 1 | Piper Sandler | Maintains | Overweight → Overweight | — | $1.77 | $2.00 | +13.0% | +64.4% | +19.9% | +4.6% | +6.6% | -9.8% |
| Aug 11 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.07 | $2.09 | +1.0% | -4.3% | +1.0% | +0.0% | -5.5% | +1.6% |
| Aug 8 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.57 | $1.67 | +6.4% | +38.9% | -12.4% | +8.4% | -4.3% | +1.0% |
| May 9 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.80 | $1.79 | -0.6% | -1.7% | -3.4% | -1.2% | +0.0% | +3.6% |
| Mar 29 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.52 | $1.54 | +1.3% | +8.6% | +0.0% | +0.0% | -2.4% | -5.0% |
| Mar 7 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.72 | $1.75 | +1.7% | +7.6% | +9.7% | -11.3% | -3.9% | -1.2% |
| Sep 16 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.67 | $1.65 | -1.2% | -5.4% | +9.5% | +0.0% | -0.6% | -4.7% |
| Sep 13 | Piper Sandler | Maintains | Overweight → Overweight | — | $3.21 | $2.50 | -22.1% | -41.1% | -14.3% | +3.1% | -5.4% | +9.5% |
| Aug 29 | Baird | Maintains | Outperform → Outperform | — | $2.62 | $2.52 | -3.8% | -5.7% | -2.4% | +11.6% | +5.6% | -1.1% |
| May 9 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.32 | $1.29 | -2.3% | -6.1% | +1.6% | -7.1% | +4.3% | +9.8% |
| Feb 28 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.87 | $2.78 | -3.1% | -6.3% | +0.0% | -5.2% | -6.3% | -1.7% |
| Dec 8 | Baird | Maintains | Outperform → Outperform | — | $5.51 | $5.80 | +5.3% | +11.1% | -5.6% | -2.8% | +0.7% | -5.5% |
| Aug 10 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $5.78 | $5.94 | +2.8% | +3.5% | -1.3% | +0.2% | -2.9% | -4.9% |
| May 10 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $9.49 | $9.48 | -0.1% | -4.0% | -4.3% | -2.5% | -0.1% | +0.7% |
| Oct 22 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $12.02 | $12.50 | +4.0% | +11.5% | +6.2% | +0.8% | +5.3% | -3.4% |
| Oct 8 | Piper Sandler | Maintains | Overweight → Overweight | — | $13.51 | $14.14 | +4.7% | +28.1% | -0.3% | -4.2% | -5.7% | -0.1% |
| Sep 18 | Maxim Group | Maintains | Buy → Buy | — | $8.11 | $8.47 | +4.4% | +7.4% | +33.2% | +0.9% | -3.1% | -5.6% |
| Mar 8 | Noble Financial | Maintains | Outperform → Outperform | — | $4.13 | $8.90 | +115.5% | +16.2% | +1.0% | -8.5% | -3.4% | -9.8% |
| Jun 15 | Maxim Group | Upgrade | Hold → Buy | — | $5.04 | $5.10 | +1.2% | -3.6% | +1.2% | +1.2% | +2.4% | -3.5% |
| Nov 10 | Maxim Group | Downgrade | Buy → Hold | — | $48.96 | $50.40 | +2.9% | -1.5% | +1.5% | -4.4% | -4.6% | -1.6% |
| Mar 16 | Piper Sandler | Downgrade | Neutral → Underweight | — | $126.00 | $100.80 | -20.0% | -25.7% | +0.0% | -9.2% | -8.5% | -7.4% |
| Aug 8 | Cantor Fitzgerald | Upgrade | Hold → Buy | — | $374.40 | $389.52 | +4.0% | +4.6% | +2.0% | -2.5% | +3.0% | +0.7% |
| Apr 26 | Leerink Swann | Downgrade | Outperform → Perform | — | $340.56 | $354.96 | +4.2% | -8.2% | +2.3% | -6.3% | -3.4% | -0.7% |
| Apr 26 | Cantor Fitzgerald | Downgrade | Buy → Hold | — | $340.56 | $354.96 | +4.2% | -8.2% | +2.3% | -6.3% | -3.4% | -0.7% |
| Apr 25 | Piper Sandler | Downgrade | Overweight → Neutral | — | $447.12 | $401.76 | -10.1% | -23.8% | -8.2% | +2.3% | -6.3% | -3.4% |
| Apr 25 | Cantor Fitzgerald | Downgrade | Buy → Hold | — | $447.12 | $401.76 | -10.1% | -23.8% | -8.2% | +2.3% | -6.3% | -3.4% |
| Mar 29 | Avondale Partners | Maintains | Market Perform → Perform | — | $367.92 | $301.68 | -18.0% | -2.0% | -5.6% | -1.7% | +3.4% | -1.5% |
| Mar 11 | Janney Capital | Downgrade | Buy → Neutral | — | $435.60 | $396.72 | -8.9% | -10.7% | +7.6% | -11.5% | +0.0% | -0.6% |
| Jan 6 | Avondale Partners | Maintains | Market Perform → Perform | — | $373.68 | $367.20 | -1.7% | -2.5% | -7.7% | +0.6% | -14.9% | -8.5% |
| Sep 15 | Cantor Fitzgerald | Maintains | Buy → Buy | — | $449.28 | $446.40 | -0.6% | +4.0% | -0.9% | +3.4% | +9.6% | -1.1% |
| Aug 14 | Leerink Swann | Maintains | Outperform → Outperform | — | $436.32 | $453.60 | +4.0% | +0.7% | +6.4% | -6.5% | -5.1% | -6.2% |
| Apr 2 | Janney Capital | Maintains | Buy → Buy | — | $486.00 | $504.00 | +3.7% | +4.4% | +0.3% | +1.8% | -0.7% | -1.4% |
| Feb 17 | Piper Sandler | Maintains | Overweight → Overweight | — | $359.28 | $369.36 | +2.8% | +8.0% | -6.3% | -1.4% | +0.6% | -1.6% |
| Jul 9 | Maxim Group | Maintains | Buy → Buy | — | $241.20 | $241.20 | +0.0% | +1.8% | -1.8% | +2.7% | -0.6% | +0.0% |
| Nov 15 | Aegis Capital | Maintains | Buy → Buy | — | $396.00 | $385.20 | -2.7% | +13.6% | -5.3% | -2.5% | -2.1% | -2.5% |
| Nov 13 | Aegis Capital | Maintains | Buy → Buy | — | $408.96 | $406.08 | -0.7% | -1.9% | -1.3% | +13.6% | -5.3% | -2.5% |
| Jul 16 | Cantor Fitzgerald | Maintains | Buy → Buy | — | $494.64 | $518.40 | +4.8% | +5.7% | -2.9% | -0.9% | +0.7% | +21.3% |
| Dec 20 | Roth Capital | Maintains | Buy → Buy | — | $497.52 | $509.76 | +2.5% | +7.2% | -1.8% | -3.2% | -2.4% | +2.0% |
| Date | Insider | Title | Type | Shares | Price | Value | Owned After | D1% | D5% |
|---|---|---|---|---|---|---|---|---|---|
| Jun 18, 2026 | PACE GARY W | — | Buy | 30,000 | $1.22 | $37K | 1,356,376 | — | — |
| Jun 18, 2026 | Mohindru Mani | Chief Executive Officer | Buy | 24,703 | $1.21 | $30K | 24,703 | — | — |
8-K · 7.01
! Medium
Cardiff Oncology, Inc. -- 8-K 7.01: Regulation FD Disclosure
Jun 3
8-K · 5.02
!!! Very High
Unknown — 8-K 5.02: Executive Change
CRDF appointed Ajay Aggarwal as CFO, signaling potential strategic shifts in financial management that investors should monitor for impacts on operational efficiency and capital allocation decisions.
Apr 9
8-K · 5.02
!!! Very High
Unknown — 8-K 5.02: Executive Change
The departure of a director or principal officer at Credify (CRDF) creates uncertainty around leadership continuity and strategic direction, potentially pressuring the stock until management clarity emerges.
Apr 2
8-K · 7.01
! Medium
Cardiff Oncology, Inc. -- 8-K 7.01: Regulation FD Disclosure
Cardiff Oncology is preparing investor presentation materials for upcoming third-party meetings, signaling potential partnership or financing discussions that could impact shareholder value.
Feb 25
8-K
Cardiff Oncology, Inc. -- 8-K Filing
Cardiff Oncology (CRDF) reports strong clinical progress for onvansertib in RAS-mutated colorectal cancer, positioning the company to advance its lead PLK1 inhibitor program into 2026.
Feb 24
Institutional (13F) — Top 20
All ↗
| # | Manager | Shares | Value | Chg | Period |
|---|---|---|---|---|---|
| 1 | Laurion Capital Management Lp | 2,646,738 | $7M | Added | Dec 2025 |
| 2 | Vanguard Capital Management Llc | 2,855,966 | $5M | New | Mar 2026 |
| 3 | Pfizer Inc | 2,411,575 | $4M | — | Mar 2026 |
| 4 | Franklin Resources Inc | 1,205,803 | $2M | — | Mar 2026 |
| 5 | Blair William & Co/il | 922,407 | $1M | Reduced | Mar 2026 |
| 6 | Morgan Stanley | 471,668 | $1M | Reduced | Dec 2025 |
| 7 | Candriam S.c.a. | 344,437 | $968K | New | Dec 2025 |
| 8 | Flputnam Investment Management Co | 595,127 | $964K | — | Mar 2026 |
| 9 | Northern Trust Corp | 493,205 | $799K | Added | Mar 2026 |
| 10 | Vanguard Portfolio Management Llc | 437,214 | $708K | New | Mar 2026 |
| 11 | Ubs Group Ag | 400,576 | $649K | Added | Mar 2026 |
| 12 | Bank Of New York Mellon Corp | 303,428 | $492K | Reduced | Mar 2026 |
| 13 | Jane Street Group, Llc | 132,850 | $373K | Reduced | Dec 2025 |
| 14 | Two Sigma Investments, Lp | 206,990 | $335K | Reduced | Mar 2026 |
| 15 | Avestar Capital, Llc | 136,145 | $221K | — | Mar 2026 |
| 16 | Nuveen, Llc | 130,346 | $211K | Added | Mar 2026 |
| 17 | Citadel Advisors Llc | 125,566 | $203K | Added | Mar 2026 |
| 18 | Renaissance Technologies Llc | 101,253 | $164K | New | Mar 2026 |
| 19 | Susquehanna International Group, Llp | 92,359 | $150K | Added | Mar 2026 |
| 20 | Assenagon Asset Management S.a. | 67,231 | $109K | — | Mar 2026 |
Mutual Funds / ETFs (N-PORT) — Top 20
All ↗
Valuation
Market Cap
$86.9M
Enterprise Value
$28.6M
P/E (TTM)
—
Forward P/E
—
PEG Ratio
0.15x
P/B
1.91x
P/S
165.51x
P/FCF
-2.29x
EV/EBITDA
—
Shares Out
66.8M
Financials (TTM)
Revenue
$525K
Net Income
-$44.8M
EBITDA
-$43.7M
Free Cash Flow
-$38.0M
Op Cash Flow
-$37.9M
EPS Basic
$-0.69
EPS Diluted
$-0.67
EPS Forward
$-0.59
Gross Margin
—
Op Margin
—
Net Margin
—
Balance Sheet
Total Assets
$61.9M
Total Liab.
$16.5M
Total Equity
$45.4M
Cash
$58.3M
LT Debt
$0
Book Value/Sh
$0.68
Debt/Equity
0.02x
Current Ratio
3.67
Quick Ratio
3.67
Returns & Growth
ROE
-101.0%
ROA
-74.1%
ROIC
-105.9%
Rev Growth YoY
-13.2%
EPS Growth YoY
+27.4%
Price Returns
2W
+9.8%
1M
+9.8%
3M
-2.1%
6M
-16.7%
12M
-44.3%
Technicals
52W High
$4.45
52W Low
$1.18
50d MA
$1.63
200d MA
$2.02
RSI (14)
41.50
ATR (14)
$0.15
Beta
1.42
Avg Volume
1.5M
Dividends
Div Rate
$0.00
Div Yield
—
Frequency
—
Ex-Div Date
—
Analyst Price Targets
Consensus
—
High
—
Low
—
Median
—
Data updated apr 25, 2026 3:07am
· Source: financialmodelingprep.com